Bionano Genomics Stock to Reverse Split on Monday, January 27th (NASDAQ:BNGO)

Bionano Genomics, Inc. (NASDAQ:BNGO) shares are scheduled to reverse split on Monday, January 27th. The 1-60 reverse split was announced on Wednesday, January 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 24th.

Bionano Genomics Trading Down 28.7 %

Bionano Genomics stock traded down $0.05 during mid-day trading on Thursday, hitting $0.13. The company’s stock had a trading volume of 31,894,418 shares, compared to its average volume of 19,639,521. The business has a 50 day moving average price of $0.23 and a 200-day moving average price of $0.37. Bionano Genomics has a 12 month low of $0.13 and a 12 month high of $1.36. The stock has a market cap of $15.47 million, a price-to-earnings ratio of -0.06 and a beta of 2.22. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.99.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH cut Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Friday, November 15th.

Hedge Funds Weigh In On Bionano Genomics

Several hedge funds and other institutional investors have recently modified their holdings of BNGO. Armistice Capital LLC bought a new stake in Bionano Genomics in the second quarter valued at $1,138,000. Geode Capital Management LLC boosted its stake in shares of Bionano Genomics by 47.3% during the 3rd quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after purchasing an additional 283,639 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Bionano Genomics during the third quarter valued at about $46,000. Finally, Carret Asset Management LLC raised its stake in Bionano Genomics by 89.0% in the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after buying an additional 40,055 shares in the last quarter. 11.35% of the stock is owned by institutional investors.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.